Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(2):193-200
The prospective study of 19 children (aged of 1 to 17 years) with invasive fungal infections and different forms of immunosupression was conducted. Clinical and microbiological efficacy and safety of caspofungin, as well as analysis of direct costs of treatment of invasive fungal infections were performed. Caspofungin is found to be efficacious and safe antifungal agent both for empirical and directed therapy of invasive candidiasis and aspergillosis in all age groups children. Analysis of direct costs showed that cost of caspofugin is a main component of direct costs in the treatment of invasive fungal infections (86 to 93%).